Imugene Ltd IMU
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- A$0.04
- Day Range
- A$0.04–0.04
- 52-Week Range
- A$0.04–0.43
- Bid/Ask
- A$0.04 / A$0.04
- Shares Outstanding
- 557.27M
- Market Cap
- A$20.62M
- Volume/Avg
- 4M / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Imugene Ltd is an Australian-headquartered clinical stage cell therapy company developing an Allogeneic CAR T for blood cancers. Its lead asset is an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. The lead asset, azer-cel, is an allogeneic CAR T cell therapy targeting CD19 positive cancer cells. Autologous CAR T therapies, which use the patient's own modified T cells, azer-cel uses donor-derived T cells that are genetically engineered to attack cancer cells. The group has identified one reportable segment, being the research and development of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
- Website
- https://www.imugene.com
Valuation
|
Metric
|
IMU
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.71 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
IMU
|
|---|---|
Quick Ratio | 0.36 |
Current Ratio | 0.70 |
Interest Coverage | −842.41 |
Quick Ratio
IMU
Profitability
|
Metric
|
IMU
|
|---|---|
Return on Assets (Normalized) | −120.22% |
Return on Equity (Normalized) | −218.47% |
Return on Invested Capital (Normalized) | −178.75% |
Return on Assets
IMU
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|tFP<<>R | LOCK|JT@$ | $129B | |||
| Moderna Inc
MRNA
| LOCK|X<^&w%# | LOCK|k$! | $85B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Gdq#M$K | LOCK|QST?C | $79B | |||
| argenx SE ADR
ARGX
| LOCK|&j$<>&s | LOCK|^D | $52B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#bgchK% | LOCK|QF | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!zkYNB | LOCK|$%<%y | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|nMRX^^Mp | LOCK|%XN$n | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|&#&zGY | LOCK|j!! | $24B | |||
| Incyte Corp
INCY
| LOCK|>?#><Y? | LOCK|^# | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|HhkPCV? | LOCK|%!y | $14B |
United States